Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2003
The purpose of this study is to compare hemoglobin (Hgb) response rates between epoetin alfa (PROCRIT; 40,000 Units (U) SC weekly) and darbepoetin alfa (ARANESP; 200 mcg every other week) in anemic cancer patients receiving chemotherapy.
Epistemonikos ID: e9cb4717739f354bc2c4f2dc924cb474384c806c
First added on: May 04, 2024